Interferon-γ-mediated hepatocarcinogenesis in mice treated with diethylnitrosamine

Laboratory Investigation

Volumn 85, Issue 5, 2005, Pages 655-663

  Matsuda, Mitsuru ^a   Nakamoto, Yasunari ^a   Suzuki, Satoshi ^b   Kurata, Tomomitsu ^c   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b HAB Research Organization   (Japan)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

Diethylnitrosamine; Gene knockout mice; Hepatocarcinogenesis; Interferon ; Oxidative DNA damage

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON; BETA INTERFERON RECEPTOR; CARCINOGEN; DIETHYLNITROSAMINE; DRINKING WATER; GAMMA INTERFERON; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; DNA DAMAGE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KNOCKOUT MOUSE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TUMOR; MACROPHAGE; MALE; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 CYP2E1; DEOXYGUANOSINE; DIETHYLNITROSAMINE; DNA DAMAGE; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERFERON TYPE II; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; WATER SUPPLY;

EID: 18744376897     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700257     Document Type: Article

References (21)

1. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-680.
2. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992;15:948-963.
3. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
4. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
5. Grisham JW. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 1997;18:59-81.
6. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188:341-350.
7. Nakamoto Y, Kaneko S, Fan H, et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 2002;196:1105-1111.
8. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996;71:57-81.
9. Corcos D, Defer N, Raymondjean M, et al. Correlated increase of the expression of the c-ras genes in chemically induced hepatocarcinomas. Biochem Biophys Res Commun 1984;122:259-264.
10. Beer DG, Schwarz M, Sawada N, et al. Expression of H-ras and c-myc protooncogenes in isolated gamma-glutamyl transpeptidase-positive rat hepatocytes and in hepatocellular carcinomas induced by diethylnitrosamine. Cancer Res 1986;46:2435-2441.
11. Smith ML, Yeleswarapu L, Locker J, et al. Expression of p53 mutant protein(s) in diethylnitrosamine-induced foci of enzyme-altered hepatocytes in male Fischer-344 rats. Carcinogenesis 1991;12:1137-1141.
12. Johnson SJ, Burr AW, Toole K, et al. Macrophage and hepatic stellate cell responses during experimental hepatocarcinogenesis. J Gastroenterol Hepatol 1998;13:145-151.
13. Ahn B, Han BS, Kim DJ, et al. Immunohistochemical localization of inducible nitric oxide synthase and 3-nitrotyrosine in rat liver tumors induced by N-nitrosodiethylamine. Carcinogenesis 1999;20:1337-1344.
14. Ikeda T, Nishimura K, Taniguchi T, et al. In Vitro Evaluation of drug interaction caused by enzyme inhibition-HAB protocol. Xenobio Metabol Dispos 2001;16:115-126.
15. Kayagaki N, Yamaguchi N, Nakayama M, et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189:1451-1460.
16. Toyonaga T, Hino O, Sugai S, et al. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci USA 1994;91:614-618.
17. Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-190.
18. Chung-man Ho J, Zheng S, Comhair SA, et al. Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res 2001;61:8578-8585.
19. Warhurst AC, Hopkins SJ, Warhurst G. Interferon gamma induces differential upregulation of alpha and beta chemokine secretion in colonie epithelial cell lines. Gut 1998;42:208-213.
20. Gal A, Tamir S, Kennedy LJ, et al. Nitrotyrosine formation, apoptosis, and oxidative damage: relationships to nitric oxide production in SJL mice bearing the RcsX tumor. Cancer Res 1997;57:1823-1828.
21. Zhuang JC, Lin C, Lin D, et al. Mutagenesis associated with nitric oxide production in macrophages. Proc Natl Acad Sci USA 1998;95:8286-8291.